Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 376

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

Open access
Goyal, Lipika, Shi, Lei, Liu, Leah Y., Fece de la Cruz, Ferran, Lennerz, Jochen K., Raghavan, Srivatsan, Leschiner, Ignaty, Elagina, Liudmila, Siravegna, Giulia, Ng, Raymond W.S., Vu, Phuong, Patra, Krushna C., Saha, Supriya K., Uppot, Raul N., Arellano, Ron, Reyes, Stephanie, Sagara, Takeshi, Otsuki, Sachie, Nadres, Brandon, Shahzade, Heather A., Dey-Guha, Ipsita, Fetter, Isobel J., Baiev, Islam, Van Seventer, Emily E., Murphy, Janet E., Ferrone, Cristina R., Tanabe, Kenneth K., Deshpande, Vikram, Harding, James J., Yaeger, Rona, Kelley, Robin K., Bardelli, Alberto, Iafrate, A. John, Hahn, William C., Benes, Cyril H., Ting, David T., Hirai, Hiroshi, Getz, Gad, Juric, Dejan, Zhu, Andrew X., Corcoran, Ryan B., Bardeesy, Nabeel·2019·Cancer Discovery

Abstract

ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary FGFR2 kinase domain mutations. Here, we report that the irreversible pan-FGFR inhibitor TAS-120 demonstrated efficacy in 4 patients with FGFR2 fusion–positive ICC who developed resistance to BGJ398 or Debio 1347. Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to BGJ398 or Debio 1347. Functional assessment and modeling the clonal outgrowth of individual resistance mutations from polyclonal cell pools mirrored the resistance profiles observed clinically for each inhibitor. Our findings suggest that strategic sequencing of FGFR inhibitors, guided by serial biopsy and ctDNA analysis, may prolong the duration of benefit from FGFR inhibition in patients with FGFR2 fusion–positive ICC. Significance: ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in FGFR2-altered ICC; however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor progression. We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomes several FGFR2 mutations in ICC models. This article is highlighted in the In This Issue feature, p. 983

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0182

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 376

Metadata

Authors
Goyal, L., Shi, L., Liu, L. Y., Fece de la Cruz, F., Lennerz, J. K., Raghavan, S., Leschiner, I., Elagina, L., Siravegna, G., Ng, R. W. S., Vu, P., Patra, K. C., Saha, S. K., Uppot, R. N., Arellano, R., Reyes, S., Sagara, T., Otsuki, S., Nadres, B., Shahzade, H. A., Dey-Guha, I., Fetter, I. J., Baiev, I., Van Seventer, E. E., Murphy, J. E., Ferrone, C. R., Tanabe, K. K., Deshpande, V., Harding, J. J., Yaeger, R., Kelley, R. K., Bardelli, A., Iafrate, A. J., Hahn, W. C., Benes, C. H., Ting, D. T., Hirai, H., Getz, G., Juric, D., Zhu, A. X., Corcoran, R. B., & Bardeesy, N.
Venue
Cancer Discovery
Published
2019-08-01
Volume
9
Issue
8
Pages
1064-1079
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2945968242
Cited by
376
References
42
FWCI
42.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-0182
The paper
Goyal, L., Shi, L., Liu, L. Y., Fece de la Cruz, F., Lennerz, J. K., Raghavan, S., Leschiner, I., Elagina, L., Siravegna, G., Ng, R. W. S., Vu, P., Patra, K. C., Saha, S. K., Uppot, R. N., Arellano, R., Reyes, S., Sagara, T., Otsuki, S., Nadres, B., . . . Bardeesy, N. (2019). TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-0182

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.